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Abstract
Purpose of Review The purpose of the review was to provide
an update of the Rome IV criteria for colorectal disorders with
implications for clinical practice.
Recent Findings The Rome diagnostic criteria are expert con-
sensus criteria for diagnosing functional gastrointestinal dis-
orders (FGIDs). The current version, Rome IV, was released in
May of 2016 after Rome III had been in effect for a decade. It
is the collective product of committees that included more
than 100 leading functional GI experts. For functional bowel
and anorectal disorders, the majority of changes relative to
Rome III are relatively minor and will have little impact on
clinical practice. However, notable changes with potential im-
pact on clinical practice and research include the changes in
the diagnostic criteria for IBS, the modified approach for
subtyping of IBS, the view on functional bowel disorders as
a spectrum of disorders, and the new definition of fecal
incontinence.
Summary New features in the Rome IV diagnostic criteria for
functional bowel and anorectal disorders will likely havemod-
est influence on clinical practice, with a few exceptions.
Keywords Functional GI disorders . Rome IV diagnostic
criteria . Functional bowel disorders . Irritable bowel
syndrome .Functionalanorectaldisorders .Fecal incontinence
Introduction
In May of 2016, the new diagnostic criteria for functional
gastrointestinal disorders, the Rome IV criteria, were pub-
lished [1]. In this review, we will provide an update on the
functional bowel and anorectal disorders as defined in Rome
IV (Tables 1 and 2) [2••, 3••] and highlight differences relative
to Rome III [4, 5], including how these changes might influ-
ence clinical practice and future research.
Overview of Rome IV
The Rome diagnostic criteria are expert consensus criteria for
diagnosing functional gastrointestinal disorders (FGIDs) that
have been in use in the field of gastroenterology for more than
a quarter of a century, since their first iteration in 1990 [6].
Over this time period, understanding of the disorders has
steadily evolved, and it has therefore been necessary to update
the criteria periodically to bring them into alignment with new
research findings and understanding of symptom patterns and
pathophysiological contributing factors. The criteria have
evolved through four successive versions. In each instance,
the updates have reflected years of hard work by teams of
experts in each of the five major functional GI domains
(esophageal, gastroduodenal, bowel, biliary, and anorectal dis-
orders), who are tasked with updating the criteria and writing
the associated documentation to ensure that the criteria are in
tune with the latest knowledge in the field [7••]. The current
version, Rome IV, was released inMay of 2016 [1] after Rome
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III had been in effect for a decade. It is the collective product
of committees that included more than 100 leading functional
GI experts. Although the new diagnostic criteria themselves
are the backbone of Rome IV, the accompanying books and
key scientific articles written by the Rome committee mem-
bers can also be considered an important part of the update.
These publications provide important reviews and reference
materials on the disorders, including comprehensive over-
views of the basic and clinical literature on the disorders,
updated treatment algorithms, and new relevant information
on gut microbiota, brain-gut interactions, physiology,
pharmacogenomics, psychosocial and cultural factors, symp-
tom subgroups within the disorders, and potential biomarkers.
Innovations that DistinguishRome IV fromRome III
The group of GI diagnoses found in Rome IV is broadly sim-
ilar to Rome III [7••]. Except for four new diagnoses that were
added in this version (reflux hypersensitivity, cannabinoid
hyperemesis syndrome, opioid-induced constipation, and nar-
cotic bowel syndrome/opioid-induced GI hyperalgesia), the
changes from Rome III consist for the most part of relatively
minor adjustments in diagnostic requirements. Both clinicians
and researchers who have relied on earlier Rome criteria will
therefore generally find the disorders defined by Rome IV
criteria to be very familiar. In nearly all cases, the key sets of
symptoms are the same as before.
Beyond changes in content of the diagnostic criteria, how-
ever, Rome IValso involved innovations in the Rome process
and philosophy. These consisted of increased empirical
grounding of the criteria as well as a partial shift in the termi-
nology used to describe the disorders.
Empirically Informed Frequency Thresholds
A significant refinement in the approach of the Rome com-
mittees in the Rome IV work was a conscious effort to make
the symptom frequency thresholds for the diagnoses evidence
based. For this purpose, a nationwide US population-based
internet survey of 1665 individuals stratified by sex, age,
and race, was conducted specifically for the Rome
Foundation [8••]. The survey included questions on all the
Rome III symptoms with new symptom frequency response
scales that had been devised for the Rome IV diagnostic ques-
tionnaire; for most symptoms, this was either a percentage
scale or a more detailed absolute-frequency scale than previ-
ously used. The resulting report provided the Rome commit-
tees with frequency distributions of symptoms in the general
population, which aided them in selecting cut-offs for the new
criteria that were most likely to separate healthy individuals
from those with abnormal symptoms. In general, the recom-
mended standard was that diagnostic thresholds for individual
symptoms should incorporate less than 10% of the general
non-clinical population (i.e., when all individuals with rele-
vant GI disorders were excluded from the analysis). This em-
pirically informed approach led to changes in the required
symptom frequencies for several diagnoses in comparison to
Rome III. The new Rome IV criteria for IBS are perhaps the
most notable example of this, as will be discussed below.
Validation of the Diagnostic Criteria Prior
to Publication
Another Rome IV refinement of the process of developing the
criteria was a much more detailed validation of the criteria
ahead of their official release than was done for earlier
Rome versions. This was accomplished by conducting a
nine-site study [8••] in the USA, UK, and Canada of 843 adult
gastroenterology clinic patients with established functional GI
diagnoses (these three countries with English-speaking popu-
lations were selected for the test because the diagnostic ques-
tionnaire was only available in English before publication).
Participating patients completed the Rome IV diagnostic
questionnaire and the agreement between clinical diagnoses
and diagnoses according to the Rome IV criteria was exam-
ined. The main focus was on three of the most common
FGIDs: irritable bowel syndrome (IBS), functional constipa-
tion (FC), and functional dyspepsia (FD). Diagnostic
Table 1 Rome IV—Bowel Disorders (2)
1.Irritable bowel syndrome (IBS)
a.IBS with predominant constipation (IBS-C)
b.IBS with predominant diarrhea (IBS-D)





5.Unspecified functional bowel disorder
6.Opioid-induced constipation
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sensitivity was moderate for IBS (62.7%) and dyspepsia
(54.7%). However, functional constipation by Rome IVonly
showed modest sensitivity (32.2%). The explanation for the
low sensitivity for that disorder seems to have been that clini-
cians tended to ignore the Rome stipulation of excluding peo-
ple whomeet IBS (and in Rome IV, also OIC) criteria from the
FC diagnosis. This is supported by the fact that follow-up
analyses in the study found that sensitivity was much better
(72.2%) if exclusion of IBS and OIC was not required for FC
diagnosis. The same study also assessed a 1-month test-retest
reliability of the new Rome criteria in the clinics and found the
same diagnoses were reproducible in about 75% of patients,
which seems quite reasonable considering that many of the
patients were receiving new treatments for their key diagnos-
tic symptoms in the meantime.
In parallel to this nine-site clinical validation study, a pop-
ulation survey of 5931 adults in the same three countries was
conducted as a part of the validation process. Those survey
data were used to evaluate the specificity of the Rome IV
criteria, i.e., their ability to accurately exclude non-patients
in the general population from the diagnoses. The specificity
of the Rome IV criteria was found to be excellent for all the
Rome IV diagnoses that could be assessed with confidence
(including 97.1% for IBS, 93.6% for FC, and 93.3% for FD).
Transition from Functional GI Disorders
to Disorders of Brain-Gut Interaction
The Rome IV criteria and their associated publications reflect
a philosophical change in the conceptualization of the family
of GI disorders they cover through reduced emphasis on the
term “functional” in their nomenclature. In recent years, there
has been growing recognition that multiple specific patho-
physiological processes play a role in functional GI disorders,
including imbalance between different types of gut bacteria,
increased gut permeability, and altered immune function.
Furthermore, the importance of neural and hormonal interac-
tion between the brain and the gut in producing and modulat-
ing the symptoms of the disorders has been recognized. For
these reasons, it has increasingly seemed to many thought
leaders in the field that applying the functional descriptor to
these disorders is overly simplistic or misleading and can pro-
mote stigmatization by fostering the inaccurate notion that
they have no real physical causes. However, it was also rec-
ognized by the committees working on Rome IV that the term
functional gastrointestinal disorders has become a widely rec-
ognized and broadly used name for this entire class of health
problems and that sudden abandonment of the word function-
al in the nomenclature of these disorders might cause confu-
sion. For this reason, a strategy of gradual shift was adopted
instead. The official Rome IV publications by the Rome
Foundation offer the alternative and preferred term
“Disorders of Gut-Brain Interaction” as a new umbrella term
for functional gastrointestinal disorders, while the older term
is used in those publications as well. Furthermore, the word
functional has been omitted in some names for individual
diagnoses and groups of diagnoses. For example, functional
esophageal disorders are now simply called esophageal disor-
ders, functional fecal incontinence is now simply fecal incon-
tinence, and functional abdominal pain syndrome has been
renamed centrally mediated abdominal pain syndrome. It is
likely that this gradual phasing out of the descriptor functional
in referring to these gut-brain disorders will continue in future
work of the Rome committees.
What Is New in the Bowel Disorders in Rome IV?
Classification
Several recent studies have highlighted the substantial overlap
between various functional bowel disorders, as well as sub-
stantial flux between these disorders and between the IBS
subtypes [9–11, 12••, 13, 14, 15••]. Therefore, in Rome IV it
is emphasized that functional bowel disorders constitute a
spectrum of GI disorders rather than isolated entities. It is
acknowledged that, even though they are characterized as dis-
tinct disorders based on diagnostic criteria, significant overlap
exists, and occasionally, it may be difficult to distinguish them
as distinct entities. Furthermore, it is also highlighted that
transition from one functional bowel disorder to another, or
from one predominant symptom to another, is frequently seen,
and this may occur as part of the natural course of the disorder,
as a response to therapy, or both. Another new feature in the
Rome IV classification of bowel disorders is a new disease
category, opioid-induced constipation (OIC), which will be
described in greater detail below.
Irritable Bowel Syndrome
Compared with Rome III [5], there are two major changes in
the IBS diagnostic criteria in Rome IV [2••]. The first is that
abdominal discomfort has been deleted from the definition,
which means that abdominal pain is now mandatory to make
the diagnosis of IBS. In Rome III, the IBS definition was “…
abdominal pain or discomfort associated with defecation or a
change in bowel habit…” [5], but in Rome IV the definition is
“…abdominal pain associated with defecation or a change in
bowel habits…” [2••]. This change was based on the impre-
cise nature of the term “discomfort,” and the fact that “dis-
comfort” is not present in every language or has different
meanings in different languages. Furthermore, it is not clear
if the distinction between discomfort and pain is qualitative or
quantitative, that the understanding of the meaning of
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discomfort varies substantially between individuals, and that it
is considered to encompass a wide range of symptoms [16].
The other major change was the change in the symptom fre-
quency threshold. In Rome IV, abdominal pain should be
present at least 1 day per week on average during the preced-
ing month, compared with at least 3 days per month in Rome
III. This was based on data obtained in the Rome normative GI
symptom survey [8••]. Both of these changes are likely to
reduce the prevalence of IBS in population-based studies,
but will probably not affect the prevalence of IBS in clinical
populations to any major degree, since most patients with IBS
acknowledge pain as one of their main symptoms [16], and the
majority of IBS patients in clinical samples have symptoms
more frequently than once per week [17]. Furthermore, slight
rewording of the IBS main criteria was also included in Rome
IV, so that the abdominal pain should be “…related to defe-
cation…” (Rome IV), instead of “…improved with defeca-
tion…” (Rome III), to emphasize the fact that a substantial
proportion of IBS patients actually reports worsening of pain
with defecation [18, 19], and/or associated with a change in
stool frequency and/or stool form. It is also acknowledged
more clearly in Rome IV compared with Rome III that the
diagnosis of IBS should bemade following several steps using
a combination of the diagnostic criteria and a limited number
of additional tests based on the presenting symptoms (the
same strategy recommended for all functional bowel
disorders).
In Rome III, IBS patients were classified into one of four
subtypes based on proportion of bowel movements with ab-
normal stool consistency as defined in the Bristol Stool Form
(BSF) scale (types 1 and 2: hard, lumpy stool; types 6 and 7:
loose, watery stools) [20, 21]; IBS with constipation (IBS-C),
IBS with diarrhea (IBS-D), IBS with mixed bowel habits
(IBS-M), or unsubtyped IBS (IBS-U) [5]. However, studies
using stool diaries with the proposed cut-off for defining the
subgroups (25% hard and/or loose stools according to BSF)
resulted in a very large proportion of subjects being defined as
IBS-U, and a very small proportion fulfilled criteria for IBS-M
[22–24], since IBS patients frequently have days with bowel
movements with normal stool consistency (BSF3-5) [12••,
17]. Moreover, when using the proposed cut-off retrospective-
ly in diagnostic questionnaires (“sometimes hard and/or loose
stools”), an exceedingly high proportion instead were catego-
rized as IBS-M [25]. Based on these shortcomings with Rome
III IBS subtyping, a new approach was suggested in Rome IV,
but with the same subtypes, i.e., IBS-C, IBS-D, IBS-M, and
IBS-U (renamed “unclassified” instead of “unsubtyped”)
[2••]. In clinical trials, 2-week stool diaries [26] using the
BSF scale is recommended, but the predominant bowel habit
for subtyping is based on stool form on days with at least one
abnormal bowel movement (BSF 1–2 or 6–7), i.e., days with
only bowel movement with normal stool consistency, BSF 3-
5, are not counted. The 25% cut-off for defining the subtypes
is also used in Rome IV: IBS-C: >25% hard stools and <25%
loose stools; IBS-D: >25% loose stools and <25% hard stools;
IBS-M: >25% loose stools and >25% hard stools; and IBS-U:
<25% loose stools and <25% hard stools. This approach will
most likely substantially reduce the IBS-U group, and increase
the IBS-M group, which reflects experience from clinical
practice. As an alternative for epidemiology or clinical prac-
tice, subjects can be shown a picture of the BSF scale and
asked to define if their abnormal bowel movements are usu-
ally constipation (BSF 1-2; IBS-C), usually diarrhea (BSF 6-
7; IBS-D), both constipation and diarrhea (IBS-M), or not
applicable since they rarely have abnormal bowel movements
(IBS-U).
Functional Constipation, Functional Diarrhea
and Functional Abdominal Bloating/Distension
For these disorders, there were minor changes in Rome IV
[2••] vs. Rome III [5]. The most notable change was that for
these disorders, where the wording “…there are insufficient
criteria for IBS…” is part of the diagnostic criteria, it is now
recognized that mild pain and/or bloating may be present, but
are not predominant symptoms in functional constipation and
functional diarrhea, and that mild pain related to bloating as
well as minor bowel movement abnormalities may be present
in functional abdominal bloating/distension. These changes
are in line with the idea that functional bowel disorders should
be thought of as existing on a continuum rather than as dis-
crete disorders, i.e., being a spectrum of chronic GI disorders
with combinations of symptoms attributable to the lower GI
tract.
For functional diarrhea, the cut-off was changed from 75%
of stools being loose in Rome III to >25% in Rome IV, but just
like in Rome III, it was acknowledged that a thorough clinical
work-up is needed before this diagnosis should be made. For
practical reasons, the 25% threshold for the symptoms includ-
ed in the diagnostic criteria for functional constipation
(straining, lumpy or hard stools, sensation of incomplete evac-
uation, sensation of anorectal blockage, use of manual maneu-
vers to facilitate defecation, and fewer than three spontaneous
bowel movement per week) was kept in the Rome IV criteria,
even though slightly different cut-offs are probably optimal
for epidemiological studies based on findings in the Rome
normative GI symptom survey [8••].
Opioid-Induced Constipation
Significant advances have been made in the area of opioid-
induced bowel dysfunction in recent years, including devel-
opment of new therapies and better understanding of underly-
ing mechanisms and differences between the various
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constellations of symptoms related to the intake of opioids
[27–29]. Even though traditionally not consistent with the
definition of a functional GI disorder (“underlying cause not
known / well defined”), it was decided to include OIC among
the functional bowel disorders in Rome IV, based on the fre-
quent overlap and shared underlying mechanisms. OIC is de-
fined in Rome IV as new or worsening symptoms of consti-
pation when initiating, changing, or increasing opioid therapy,
that must include two or more of the symptoms defining func-
tional constipation (see above) with the same frequency cut-
off (25%). Furthermore, narcotic bowel syndrome or opioid-
induced GI hyperalgesia, characterized by paradoxical devel-
opment of, or increase in, abdominal pain associated with
continuous or increasing dosages of opioids, was also includ-
ed in Centrally Mediated Disorders of GI Pain in Rome IV, a
diagnostic category which was also new relative to Rome III
[30••]. Given the increasing use of opioids in the US and in
other parts of the world, these entities will most likely be more
commonly seen in clinical practice in the coming years, and
important to manage appropriately [31]. Hence, these updates
in the diagnostic criteria seem clinically important.
What Is New in the Anorectal Disorders in Rome IV?
Fecal Incontinence
The diagnostic criteria for fecal incontinence underwent sub-
stantial changes between Rome III and Rome IV: Rome III
attempted to distinguish Functional Fecal Incontinence from
structural or neurogenic causes [4] whereas Rome IV defines
Fecal Incontinence (FI; not functional fecal incontinence) sim-
ply as the uncontrolled passage of solid or liquid stool with no
distinction made on the basis of presumed etiology [3••]. This
reflects an emerging consensus that there are multiple, over-
lapping factors that contribute to the occurrence of FI and that
patients for whom the causes of FI are primarily psychological
or related to bowel habit abnormalities are rare. Moreover, the
distinction between functional and structural or neurological
causes has not been found to be a reliable guide to effective
treatment. Although this is a major conceptual change in the
way the Rome criteria define FI, it will not have a great impact
on clinical practice because most clinicians already diagnose
and treat based on the assumption that there is no clear dis-
tinction between functional and structural causes of FI.
A second change in the diagnostic criteria for FI is to re-
quire, at least for research purposes, that stool leakage occur at
least two times in a 4-week period to qualify for the diagnosis.
By contrast, Rome III required only “recurrent” (i.e., more
than one) episodes of stool leakage in the past 3 months.
This more restrictive frequency threshold in Rome IV will
result in fewer patients with mild or infrequent stool leakage
meeting the criteria for FI and may result in lower estimates of
the prevalence of FI. Research is needed to determine whether
this frequency threshold reliably distinguishes between pa-
tients with infrequent and mild stool leakage who have less
quality of life impairment and are satisfied to manage on their
own vs. patients with more frequent stool leakage who may
benefit from treatments available through a physician.
Rectal Pain Syndromes
Changes from Rome III to Rome IV in the diagnostic classi-
fication of functional anorectal pain syndromes are relatively
few and are unlikely to have a significant impact on clinical
practice:
The term “chronic proctalgia” was dropped from the clas-
sification system. The Rome III criteria [4] distinguished two
major types of anorectal pain: chronic proctalgia and
proctalgia fugax, based on differences in the quality of pain
(dull pain or aching in chronic proctalgia vs. sharp or stabbing
pain in proctalgia fugax) and duration of pain episodes (chron-
ic pain present most of the time or for periods greater than
20 min in chronic proctalgia vs. fleeting, brief pain episodes
(20 min or less) separated by pain-free periods in proctalgia
fugax). In Rome III, chronic proctalgia was further subdivided
into levator ani syndrome if traction on the levator muscles
during digital rectal examination elicited a report of tenderness
or pain, vs. unspecified functional anorectal pain if such dig-
ital traction did not elicit a report of tenderness. However, a
factor analysis study [32] of a population sample of young
adults did not identify distinct clusters of symptoms for chron-
ic proctalgia vs. proctalgia fugax, so the term “chronic
proctalgia” was eliminated from the classification system in
Rome IV [3••]. Nevertheless, because the pathophysiological
mechanisms and treatment indications for these two disorders
may differ, the distinction between levator ani syndrome, un-
specified functional anorectal pain, and proctalgia fugax were
preserved in Rome IV.
The maximum duration of pain episodes separating
proctalgia fugax from levator ani syndrome and unspecified
functional anorectal pain was changed from 20 min to 30 min
based on anecdotal evidence that proctalgia fugax “attacks”
sometimes last up to 30 min. Moreover, the location of pain in
proctalgia fugax is the rectum in Rome IV; it was described as
“lower rectum or anus” in Rome III.
The most significant innovation in the area of rectal pain
syndromes relates to treatment and new insights into the path-
ophysiology of pain in levator ani syndrome, based on results
from a randomized controlled trial comparing the three most
commonly employed treatment strategies for chronic
proctalgia (biofeedback, electrical stimulation of the anal ca-
nal, and massage of the levator muscles) [33••]. This study
demonstrated that biofeedback (a protocol identical to the one
used for correcting dyssynergic defecation) is the preferred
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treatment, but if biofeedback is not available, electrical stim-
ulation may also be beneficial. Furthermore, the best predictor
of the success of biofeedback treatment is a digital rectal exam
showing tenderness with traction on the striated levator ani
muscles, and the physiological mechanisms associated with
clinical improvements in levator ani syndrome were acquisi-
tion of the ability to relax pelvic floor muscles when
attempting to evacuate and acquisition of the ability to evac-
uate a water-filled balloon. These findings suggest similarities
in the pathophysiological mechanisms between levator ani
syndrome and pelvic floor dyssynergia even though the pa-
tients in this study did not report symptoms of constipation.
Functional Defecation Disorders
The Rome IV working team introduced a number of changes
to the diagnostic criteria for functional defecation disorders
which are listed below. However, these are unlikely to signif-
icantly changewhich patients receive a diagnosis of functional
defecation disorder or the indications for treatment.
The Rome III criteria required that the patient must meet
symptom criteria for Functional Constipation. However, in
deference to new data showing a strong overlap between func-
tional constipation and irritable bowel syndrome with consti-
pation (IBS-C) [15••, 34, 35], the Rome IV criteria state that
the patient may fulfill this criterion by meeting symptom
criteria for either functional constipation or IBS-C.
As with Rome III, the criteria for functional defecation
disorders also require the presence of at least two of three
objective physiological tests, but the nature of the three qual-
ifying tests has changed: In Rome III, the first criterion was
evidence of impaired evacuation by either an abnormal bal-
loon evacuation test or imaging. In Rome IV, these have been
separated; abnormal balloon expulsion is one criterion and an
imaging study showing inadequate evacuation is a separate
qualifying criterion. The Rome III list of qualifying criteria
included inadequate rectal propulsive force, but this has been
dropped from Rome IV. The third qualifying criterion is now
described as an abnormal anorectal evacuation pattern
assessed by anal manometry or surface EMG but, unlike
Rome III, there is no specific definition of what an abnormal
evacuation pattern is.
Both Rome IV and Rome III criteria define Inadequate
Defecatory Propulsion and Dyssynergic Defecation as sub-
types of Functional Defecation Disorders, and the criteria for
this distinction are identical in Rome III and Rome IV.
Although the diagnostic criteria for functional defecation
disorders remain largely the same in Rome IV, there is an
emerging controversy in the field which may have an impact
on clinical practice: Over the past 5–10 years, high-resolution/
high-definition anorectal manometry equipment has been
more widely disseminated, at least in academic medical
centers. The expectation was that these systems would im-
prove the diagnostic accuracy of anorectal manometry be-
cause the amount of data reported out is more than an order
of magnitude greater [36]. However, two different research
teams have found that more than 80% of healthy controls
show evidence of paradoxical contraction or failure to relax
the pelvic floor muscles when performing simulated defeca-
tion maneuvers [37••, 38]. This is inconsistent with earlier
reports of a low frequency of paradoxical contraction in
healthy subjects when perfusion manometry or manometry
catheters with only a few solid state pressure transducers were
used, and it calls into question the whole concept of
dyssynergic defecation and the criteria that have been used
to make this diagnosis. These observations also challenge
the basis for pelvic floor biofeedback to treat disordered def-
ecation despite multiple randomized controlled trials showing
biofeedback training for pelvic floor relaxation to be a highly
effective treatment for patients with difficulty evacuating the
rectum [39–41]. The outcome of this controversy will inevi-
tably have a significant impact on the standards for diagnosis
and management of functional defecation disorders.
Conclusion
In this review, we have provided an update on the most recent
diagnostic criteria for functional bowel and anorectal disor-
ders, the Rome IV criteria [2••, 3••]. The majority of changes
relative to Rome III [4, 5] are relatively minor and will have
little impact on clinical practice. However, notable changes
with potential impact on clinical practice and research include
the changes in the diagnostic criteria for IBS, the modified
approach for subtyping of IBS, the new perspective on func-
tional bowel disorders as a spectrum of disorders, and the new
definition of fecal incontinence that makes no distinction
based on presumed etiology. Furthermore, a new diagnostic
entity, opioid-induced constipation, was included among the
functional bowel disorders in Rome IV.
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